Search

Displaying results 3161 - 3170 of 7503 in total
  1. Drug

    Glisoxepide

    go.drugbank.com/drugs/DB01289
    Investigational

    by sulphate. … Glisoxepide uptake could be further inhibited by blockers of the hepatocellular monocarboxylate transporter, by the loop diuretic bumetanide, by 4,4'-diisothiocyano-2,2'-stilbenedisulfonate (DIDS) and

  2. Drug

    G207

    go.drugbank.com/drugs/DB05827
    Investigational

    G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG. … MediGene uses these viruses, however, in a modified and "disarmed" form in order to make them utilizable as a therapeutic agent in humans.

  3. Drug

    Lysergic acid diethylamide

    go.drugbank.com/drugs/DB04829
    IllicitInvestigational

    Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. … Some say HPPD is a manifestation of post-traumatic stress disorder, not related to the direct action of LSD on brain chemistry, and varies according to the susceptibility of the individual to the disorder

    Synonyms: N,N-diethyllysergamide, N,N-diethyl-D-lysergamideCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  4. Drug

    KC706

    go.drugbank.com/drugs/DB05157
    Investigational

    KC706 is a novel anti-inflammatory drug that works by inhibiting the activity of p38 MAP kinase. … KC706 holds potential to treat inflammatory conditions such as rheumatoid arthritis, psoriasis, inflammatory bowel disease and cardiovascular disease.

  5. Drug

    Reglitazar

    go.drugbank.com/drugs/DB04971
    Experimental

    Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.

  6. Drug

    Indium In-111 satumomab pendetide

    go.drugbank.com/drugs/DB00057
    ApprovedWithdrawn

    Satumomab Pendetide (trade name: OncoScint®) is no longer commercially available.

  7. Drug

    NV-18

    go.drugbank.com/drugs/DB05886
    Experimental

    Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma (cancer … NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer.

  8. Drug

    Elvitegravir

    go.drugbank.com/drugs/DB09101
    ApprovedInvestigational

    Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012. … On September 24, 2014, the FDA approved the single pill form of elvitegravir.

  9. Drug

    Dirucotide

    go.drugbank.com/drugs/DB04921
    Investigational

    Developed at the University of Alberta, dirucotide is being investigated by BioMS Medical Corp. … In particular, the sequence prepared is a 17 amino acid chain that is identical to a section of myelin basic protein (MBP) that is found in humans.

  10. Drug

    Copper oxodotreotide Cu-64

    go.drugbank.com/drugs/DB15873
    Approved

    [A220348] Copper Cu 64 dotatate has a longer half-life and can be produced once a day as opposed to several times a day, and lower positron energy lending to improved spatial resolution. … [A220348] Further studies should be performed to compare the two tracers.